<DOC>
	<DOCNO>NCT02592798</DOCNO>
	<brief_summary>The purpose study evaluate abatacept effective safe decrease level protein loss urine patient excessive loss protein urine ( nephrotic syndrome ) due either focal segmental glomerulosclerosis ( FSGS ) minimal change disease ( MCD ) . Candidates must prior kidney biopsy either diagnosis . Another kidney biopsy require part study . Candidates must fail intolerant prior therapy kidney disease . The failed intolerant therapy must include corticosteroid least one drug . Candidates adults child age 6 . Abatacept administer venous infusion every 4 week .</brief_summary>
	<brief_title>Pilot Study Evaluate Safety Efficacy Abatacept Adults Children 6 Years Older With Excessive Loss Protein Urine Due Either Focal Segmental Glomerulosclerosis ( FSGS ) Minimal Change Disease ( MCD )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Male female subject age ≥ 6 year Subjects resistant corticosteroid , calcineurin inhibitor ( cyclosporine tacrolimus ) , sirolimus , mycophenolate mofetil ( MMF ) , mycophenolic acid ( MPA ) , cyclophosphamide intolerant least 2 UPCR ≥ 3 screen FSGS MCD confirm renal biopsy eGFR ≥ 60 child ≥ 45 adult Concomitant use angiotensinconvertingenzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) stable dos least 2 week Kidney diseases FSGS MCD Collapsing FSGS Systemic lupus erythematosus Diabetes mellitus , type 1 type 2 Clinically significant congestive heart failure Body mass index ( BMI ) : &gt; 40 subject ≥ 18 year age ≥ 99 % percentile subject &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>